- Home
- ACRS vs FNWD Comparison
ACRS vs FNWD Comparison
Compare ACRS & FNWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FNWD
- Stock Information
- Founded
- ACRS 2012
- FNWD 1994
- Country
- ACRS United States
- FNWD United States
- Employees
- ACRS N/A
- FNWD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FNWD Savings Institutions
- Sector
- ACRS Health Care
- FNWD Finance
- Exchange
- ACRS Nasdaq
- FNWD Nasdaq
- Market Cap
- ACRS 165.7M
- FNWD 137.3M
- IPO Year
- ACRS 2015
- FNWD N/A
- Fundamental
- Price
- ACRS $1.84
- FNWD $31.77
- Analyst Decision
- ACRS Strong Buy
- FNWD Buy
- Analyst Count
- ACRS 9
- FNWD 1
- Target Price
- ACRS $9.25
- FNWD $34.00
- AVG Volume (30 Days)
- ACRS 815.1K
- FNWD 21.5K
- Earning Date
- ACRS 11-05-2025
- FNWD 10-23-2025
- Dividend Yield
- ACRS N/A
- FNWD 1.50%
- EPS Growth
- ACRS N/A
- FNWD N/A
- EPS
- ACRS N/A
- FNWD 1.24
- Revenue
- ACRS $16,789,000.00
- FNWD $63,780,000.00
- Revenue This Year
- ACRS N/A
- FNWD N/A
- Revenue Next Year
- ACRS N/A
- FNWD $7.77
- P/E Ratio
- ACRS N/A
- FNWD $25.77
- Revenue Growth
- ACRS N/A
- FNWD N/A
- 52 Week Low
- ACRS $1.05
- FNWD $26.12
- 52 Week High
- ACRS $5.17
- FNWD $33.50
- Technical
- Relative Strength Index (RSI)
- ACRS 47.21
- FNWD 52.44
- Support Level
- ACRS $2.01
- FNWD N/A
- Resistance Level
- ACRS $2.16
- FNWD $32.18
- Average True Range (ATR)
- ACRS 0.11
- FNWD 0.65
- MACD
- ACRS -0.03
- FNWD -1.28
- Stochastic Oscillator
- ACRS 14.86
- FNWD 96.55
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About FNWD Finward Bancorp
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.